Weill-Cornell-New York Presbyterian Hospital
Welcome,         Profile    Billing    Logout  
 19 Trials 
25 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Horn, Evelyn
NCT03626688 / 2018-001187-33: A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients

Recruiting
3
1000
Europe, Canada, US, RoW
Ralinepag, APD811, Placebo
United Therapeutics
PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension, Connective Tissue Diseases, Familial Primary Pulmonary Hypertension, Vascular Diseases, Cardiovascular Diseases, Hypertension, Pulmonary, Lung Diseases, Respiratory Tract Disease
12/25
12/25
NCT05977933: Assessing the Utility of Submaximal CPET in Treatment Management of PAH

Not yet recruiting
N/A
550
US
Shape II CPET
Shape Medical Systems, Inc., National Heart, Lung, and Blood Institute (NHLBI)
Pulmonary Arterial Hypertension
09/24
12/24
ASPIRE PH, NCT04555161: Treatment of Pulmonary Arterial Hypertension Using the Aria CV Pulmonary Hypertension System

Recruiting
N/A
30
US
Aria CV Pulmonary Hypertension System, Aria CV PH System
Aria CV, Inc
Pulmonary Arterial Hypertension, Pulmonary Hypertension, Right Heart Dysfunction
10/25
10/26
Ramani, Gautam
NCT03626688 / 2018-001187-33: A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients

Recruiting
3
1000
Europe, Canada, US, RoW
Ralinepag, APD811, Placebo
United Therapeutics
PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension, Connective Tissue Diseases, Familial Primary Pulmonary Hypertension, Vascular Diseases, Cardiovascular Diseases, Hypertension, Pulmonary, Lung Diseases, Respiratory Tract Disease
12/25
12/25
McConnell, John
NCT03626688 / 2018-001187-33: A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients

Recruiting
3
1000
Europe, Canada, US, RoW
Ralinepag, APD811, Placebo
United Therapeutics
PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension, Connective Tissue Diseases, Familial Primary Pulmonary Hypertension, Vascular Diseases, Cardiovascular Diseases, Hypertension, Pulmonary, Lung Diseases, Respiratory Tract Disease
12/25
12/25
NCT05983250: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF

Recruiting
3
152
Canada, US
TNX-103, Placebo
Tenax Therapeutics, Inc., Medpace, Inc., Northwestern University
Pulmonary Hypertension
03/27
07/27
ELEVATE 2, NCT04712669 / 2020-004971-42: A Study of Rodatristat Ethyl in Patients With Pulmonary Arterial Hypertension

Completed
2
108
Europe, Canada, US, RoW
rodatristat ethyl 300 mg tablet BID, rodatristat ethyl 600 mg BID, Placebo
Altavant Sciences GmbH
Pulmonary Arterial Hypertension
06/23
08/23
Ravichandran, Ashwin
NCT03626688 / 2018-001187-33: A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients

Recruiting
3
1000
Europe, Canada, US, RoW
Ralinepag, APD811, Placebo
United Therapeutics
PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension, Connective Tissue Diseases, Familial Primary Pulmonary Hypertension, Vascular Diseases, Cardiovascular Diseases, Hypertension, Pulmonary, Lung Diseases, Respiratory Tract Disease
12/25
12/25
COMPETENCE, NCT01187368: Prospective Multi-Center Randomized Study for Evaluating the EVAHEART®2 Left Ventricular Assist System

Suspended
N/A
399
US
EVAHEART Left Ventricular Assist System (LVAS), EVA2, HeartMate 3, HM3
Evaheart, Inc.
Heart Failure
07/27
07/28
PROACTIVE-HF, NCT04089059: IDE Trial Heart Failure NYHA Class III

Active, not recruiting
N/A
457
Europe, US
Cordella™ Pulmonary Artery Sensor System
Endotronix, Inc.
Heart Failure NYHA Class III
04/28
04/28
ASCENT, NCT06129240: An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in PH

Recruiting
N/A
60
US
LIQ861
Liquidia Technologies, Inc.
Pulmonary Hypertension, Interstitial Lung Disease
07/26
10/26
ASPIRE PH, NCT04555161: Treatment of Pulmonary Arterial Hypertension Using the Aria CV Pulmonary Hypertension System

Recruiting
N/A
30
US
Aria CV Pulmonary Hypertension System, Aria CV PH System
Aria CV, Inc
Pulmonary Arterial Hypertension, Pulmonary Hypertension, Right Heart Dysfunction
10/25
10/26
NCT05934487: PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and III

Recruiting
N/A
1650
US
Cordella™ Pulmonary Artery Sensor System
Endotronix, Inc.
Heart Failure NYHA Class II, Heart Failure NYHA Class III
09/27
09/29
Reynolds, Dolores
NCT03626688 / 2018-001187-33: A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients

Recruiting
3
1000
Europe, Canada, US, RoW
Ralinepag, APD811, Placebo
United Therapeutics
PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension, Connective Tissue Diseases, Familial Primary Pulmonary Hypertension, Vascular Diseases, Cardiovascular Diseases, Hypertension, Pulmonary, Lung Diseases, Respiratory Tract Disease
12/25
12/25
NCT05163548: PerQseal®+ Early Feasibility Study

Completed
N/A
15
US
PerQseal Plus Device, Vascular Closure Device
Vivasure Medical Limited
Percutaneous Large Hole Vascular Closure
07/22
07/22
NCT04890821: Early Feasibility Study of the Cardiac Implants Percutaneous Ring Annuloplasty System

Recruiting
N/A
15
US
CI Percutaneous Ring Annuloplasty System
Cardiac Implants LLC
Tricuspid Regurgitation Functional
08/22
09/27
CorCinch-HF, NCT04331769: Clinical Evaluation of the AccuCinch® Ventricular Restoration System in Patients Who Present with Symptomatic Heart Failure with Reduced Ejection Fraction (HFrEF): the CORCINCH-HF Study

Recruiting
N/A
400
Europe, US, RoW
AccuCinch Ventricular Restoration System, Guideline-Directed Medical Therapy
Ancora Heart, Inc.
Heart Failure with Reduced Ejection Fraction (HFrEF), Dilated Cardiomyopathy
12/26
12/30
NCT05977933: Assessing the Utility of Submaximal CPET in Treatment Management of PAH

Not yet recruiting
N/A
550
US
Shape II CPET
Shape Medical Systems, Inc., National Heart, Lung, and Blood Institute (NHLBI)
Pulmonary Arterial Hypertension
09/24
12/24
AIM HIGHer, NCT05064709: Assessment of CCM in HF with Higher Ejection Fraction

Recruiting
N/A
1500
US
Cardiac Contractility Modulation Therapy via OPTIMIZER™ Smart Mini System, CCM Group (CCM ON), OPTIMIZER™ Smart Mini System, Sham Group (CCM OFF)
Impulse Dynamics
Heart Failure, Heart Failure with Preserved Ejection Fraction, Heart Failure with Mid Range Ejection Fraction, Heart Failure with Moderately Reduced Ejection Fraction, Diastolic Heart Failure
02/25
02/26
PROTEMBO, NCT05873816: The Trial

Recruiting
N/A
500
NA
ProtEmbo - Cerebral Embolic Protection, Sentinel - Cerebral Embolic Protection
Protembis GmbH
Severe Aortic Valve Stenosis
06/25
07/25
rēST Study, NCT03884660: Remedē System Therapy Study

Recruiting
N/A
500
Europe, US
remede System
Respicardia, Inc.
Central Sleep Apnea
06/27
06/32
Poliakova, Lioubov
NCT03626688 / 2018-001187-33: A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients

Recruiting
3
1000
Europe, Canada, US, RoW
Ralinepag, APD811, Placebo
United Therapeutics
PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension, Connective Tissue Diseases, Familial Primary Pulmonary Hypertension, Vascular Diseases, Cardiovascular Diseases, Hypertension, Pulmonary, Lung Diseases, Respiratory Tract Disease
12/25
12/25
Malla, Bipin
NCT03626688 / 2018-001187-33: A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients

Recruiting
3
1000
Europe, Canada, US, RoW
Ralinepag, APD811, Placebo
United Therapeutics
PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension, Connective Tissue Diseases, Familial Primary Pulmonary Hypertension, Vascular Diseases, Cardiovascular Diseases, Hypertension, Pulmonary, Lung Diseases, Respiratory Tract Disease
12/25
12/25
VIPAH-PRN 2B, NCT04266197: Vardenafil Inhaled for Pulmonary Arterial Hypertension PRN Phase 2B Study

Active, not recruiting
2
42
US
Drug: RT234 - vardenafil inhalation powder; Device: Axially Oscillating Sphere dry powder inhaler (AOS DPI), inhaled vardenafil
Respira Therapeutics, Inc.
Pulmonary Arterial Hypertension
11/24
12/24
PASC VQ, NCT05866952: Ventilatory and Perfusion Abnormalities in Individuals with Post-Acute Sequelae of SARS-CoV-2 Infection

Recruiting
N/A
40
US
Computed Tomography of the Chest
Tufts Medical Center, 4DMedical
Post-Acute COVID-19, Post COVID-19 Condition, Post Viral Fatigue, Dyspnea
05/25
12/25

Download Options